Torrent Pharma records 15.4% growth in net profit for FY25

 The revenues from the domestic market stood at ₹6,393 crore, a growth of 13 per cent

Aided by revenue growth in markets in the US, Germany and India, Torrent Pharmaceuticals, the flagship entity of Gujarat-based Torrent Group on Tuesday posted a ₹1,911 crore consolidated net profit for financial year 2024-25, a 15.4 per cent year-on-year rise.

The annual revenues of the company grew by 7.1 per cent to ₹11,317 crore. The revenues from the domestic market stood at ₹6,393 crore, a growth of 13 per cent. In the fourth quarter of financial year 2025, the revenue growth was led by focus therapies. On Tuesday, the Board of Directors recommended a final dividend of ₹6 per share.

Revenue elsewhere

Revenues from Germany and the US also saw an uptick during the last fiscal year. While revenues from Germany grew by six percent to ₹1,139 crore, those from the US grew two per cent to ₹1,100 crore. The business from Brazil was a tad disappointing for the company where it mopped up ₹1,100 crore in revenues, a decline of two per cent. Impacted by steep Brazilian Real depreciation, the revenues of the company slid southwards by six per cent. Torrent Pharmaceuticals has presence in 50-plus countries and is ranked number one amongst the Indian pharma Companies in Brazil and Germany.  

On a MAT (Moving Annual Total) basis, Torrent has outperformed the market across focused therapies aided by strong new launch performance, the company stated. Torrent has 21 brands in the Top 500 brands in Indian Pharmaceutical Market, with 14 brands having more than ₹100 crore sales, the company added.

Torrent Pharmaceuticals is ranked seventh in the Indian Pharmaceuticals Market and is amongst the top five in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with about 76 per cent of its revenues in India from chronic and sub- chronic therapies. 

As part of the company’s long-term strategic vision and succession planning, the Board of Directors also approved the appointment of Aman Mehta as Managing Director, effective August 1, 2025.

Published on May 20, 2025